Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy : A case report
© 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology..
Pulmonary pleomorphic carcinoma (PPC) is a rare type of non-small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), has been approved as the first-line treatment for advanced NSCLC with robust PD-L1 expression in at least 50% of tumour cells, without epidermal growth factor receptor gene (EGFR) mutations or anaplastic lymphoma kinase gene (ALK) rearrangement. Here, we report the case of an 81-year-old man with multiple comorbidities who was diagnosed with PPC and showed a robust response to pembrolizumab followed by radiation therapy without adverse effects. In the absence of randomized clinical trials for PPCs, our case report demonstrates the potential application of pembrolizumab and radiation therapy for the treatment of PPCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Respirology case reports - 9(2021), 12 vom: 11. Dez., Seite e0875 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Tae-Hun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 04.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/rcr2.875 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333332997 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333332997 | ||
| 003 | DE-627 | ||
| 005 | 20240404233011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rcr2.875 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM333332997 | ||
| 035 | |a (NLM)34795901 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Tae-Hun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy |b A case report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. | ||
| 520 | |a Pulmonary pleomorphic carcinoma (PPC) is a rare type of non-small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death-1 (PD-1), has been approved as the first-line treatment for advanced NSCLC with robust PD-L1 expression in at least 50% of tumour cells, without epidermal growth factor receptor gene (EGFR) mutations or anaplastic lymphoma kinase gene (ALK) rearrangement. Here, we report the case of an 81-year-old man with multiple comorbidities who was diagnosed with PPC and showed a robust response to pembrolizumab followed by radiation therapy without adverse effects. In the absence of randomized clinical trials for PPCs, our case report demonstrates the potential application of pembrolizumab and radiation therapy for the treatment of PPCs | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a PD‐L1 | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a pulmonary pleomorphic carcinoma | |
| 700 | 1 | |a Park, Sun Hyo |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Ilseon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jin Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jin Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hae Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyun Jung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology case reports |d 2013 |g 9(2021), 12 vom: 11. Dez., Seite e0875 |w (DE-627)NLM244269440 |x 2051-3380 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:12 |g day:11 |g month:12 |g pages:e0875 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rcr2.875 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 12 |b 11 |c 12 |h e0875 | ||